Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter

Journal of Interventional Cardiac Electrophysiology

Volumn 37, Issue 3, 2013, Pages 241-247

  Kaiser, Daniel W ^a   Streur, Megan M ^a   Nagarakanti, Rangadham ^a   Whalen, S Patrick ^a   Ellis, Christopher R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Catheter ablation; Complications; Dabigatran

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; COMORBIDITY; EMBOLISM; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TENNESSEE; TREATMENT OUTCOME; WARFARIN;

EID: 84882287234     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-013-9793-7     Document Type: Article

References (26)

1. Fisher, J. D.; Spinelli, M. A.; Mookherjee, D.; Krumerman, A. K.; & Palma, E. C. (2006). Atrial fibrillation ablation: reaching the mainstream. [Meta-analysis research support, Non-US Gov't Review]. Pacing and Clinical Electrophysiology: PACE, 29(5), 523-537.
2. Cappato, R.; Calkins, H.; Chen, S. A.; Davies, W.; Iesaka, Y.; Kalman, J.; et al. (2010). Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. Arrhythmia and Electrophysiology, 3(1), 32-38.
3. Scherr, D.; Sharma, K.; Dalal, D.; Spragg, D.; Chilukuri, K.; Cheng, A.; et al. (2009). Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. [Research support, Non-US Gov't]. Journal of Cardiovascular Electrophysiology, 20(12), 1357-1363.
4. Vazquez, S. R.; Johnson, S. A.; & Rondina, M. T. (2010). Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. [Review]. Thrombosis Research, 126(2), e69-e77.
5. Viles-Gonzalez, J. F.; & Mehta, D. (2011). Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. [Review]. Current Cardiology Reports, 13(1), 38-42.
6. Di Biase, L.; Burkhardt, J. D.; Mohanty, P.; Sanchez, J.; Horton, R.; Gallinghouse, G. J.; et al. (2010). Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. [Comparative study multicenter study research support, Non-US Gov't]. Circulation, 121(23), 2550-2556.
7. Hakalahti, A.; Uusimaa, P.; Ylitalo, K.; & Raatikainen, M. J. (2011). Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. [Clinical trial research support, Non-US Gov't]. Europace, 13(5), 640-645.
8. Hussein, A. A.; Martin, D. O.; Saliba, W.; Patel, D.; Karim, S.; Batal, O.; et al. (2009). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 6(10), 1425-1429.
9. Santangeli, P.; Di Biase, L.; Sanchez, J. E.; Horton, R.; & Natale, A. (2011). Atrial fibrillation ablation without interruption of anticoagulation. Cardiology Research and Practice, 2011, 837841.
10. Wazni, O. M.; Beheiry, S.; Fahmy, T.; Barrett, C.; Hao, S.; Patel, D.; et al. (2007). Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. [Clinical trial comparative study controlled clinical trial]. Circulation, 116(22), 2531-2534.
11. Abhishek, F.; Heist, E. K.; Barrett, C.; Danik, S.; Blendea, D.; Correnti, C.; et al. (2011). Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. [Research Support, Non-US Gov't]. Journal of Interventional Cardiac Electrophysiology: An International Journal of Arrhythmias and Pacing, 30(3), 211-215.
12. Wann, L. S.; Curtis, A. B.; Ellenbogen, K. A.; Estes, N. A.; 3rd, Ezekowitz, M. D.; Jackman, W. M.; et al. (2011). 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. [Practice guideline]. Journal of the American College of Cardiology, 57(11), 1330-1337.
13. Connolly, S. J.; Ezekowitz, M. D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. [Comparative study multicenter study randomized controlled trial research support, Non-US Gov't]. The New England Journal of Medicine, 361(12), 1139-1151.
14. Calkins, H.; Kuck, K. H.; Cappato, R.; Brugada, J.; Camm, A. J.; Chen, S. A.; et al. (2012). 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace, 14(4), 528-606.
15. Lakkireddy, D.; Reddy, Y. M.; Di Biase, L.; Vanga, S. R.; Santangeli, P.; Swarup, V.; et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 59(13), 1168-1174.
16. van Ryn, J.; Stangier, J.; Haertter, S.; Liesenfeld, K. H.; Wienen, W.; Feuring, M.; et al. (2010). Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. [Review]. Thrombosis and Haemostasis, 103(6), 1116-1127.
17. Stangier, J.; Rathgen, K.; Stahle, H.; Gansser, D.; & Roth, W. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. [Randomized controlled trial]. British Journal of Clinical Pharmacology, 64(3), 292-303.
18. Stangier, J.; Eriksson, B. I.; Dahl, O. E.; Ahnfelt, L.; Nehmiz, G.; Stahle, H.; et al. (2005). Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. [Clinical trial clinical trial, phase i clinical trial, phase ii multicenter study randomized controlled trial research support, Non-US Gov't]. The Journal of Clinical Pharmacology, 45(5), 555-563.
19. Stangier, J.; Stahle, H.; Rathgen, K.; & Fuhr, R. (2008). Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. [Randomized controlled trial research support, Non-US Gov't]. Clinical Pharmacokinetics, 47(1), 47-59.
20. Garnock-Jones, K. P. (2011). Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions, 11(1), 57-72.
21. Sanford, M.; & Plosker, G. L. (2008). Dabigatran etexilate. Drugs, 68(12), 1699-1709.
22. Takahashi, A.; Kuwahara, T.; & Takahashi, Y. (2009). Complications in the catheter ablation of atrial fibrillation: incidence and management. [Review]. Circulation Journal, 73(2), 221-226.
23. Gaita, F.; Caponi, D.; Pianelli, M.; Scaglione, M.; Toso, E.; Cesarani, F.; et al. (2010). Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. [comparative study multicenter study]. Circulation, 122(17), 1667-1673.
24. Knight, B. P. (2012). Anticoagulation for atrial fibrillation ablation: what is the optimal strategy? [Comment editorial]. Journal of the American College of Cardiology, 59(13), 1175-1177.
25. Stangier, J.; Rathgen, K.; Stahle, H.; & Mazur, D. (2010). Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. [Clinical trial research support, Non-US Gov't]. Clinical Pharmacokinetics, 49(4), 259-268.
26. Winkle, R. A.; Mead, R. H.; Engel, G.; Kong, M. H.; & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23(3), 264-268.